Search

Displaying results 2931 - 2940 of 5898 in total
  1. Drug

    Relatlimab

    go.drugbank.com/drugs/DB14851
    ApprovedInvestigational

    [L41265,L41300] It was the first anti-LAG-3 antibody to demonstrate benefit in a Phase 3 study, as well as the first to receive FDA approval. … [L41300] Opdualag was subsequently approved in the European Union in July 2022[L49996] and in Canada in September 2023.[L50001]

  2. Drug

    Taurolidine

    go.drugbank.com/drugs/DB12473
    ApprovedInvestigational

    Taurolidine is an antimicrobial used for the prevention of catheter-related infections. It is a derivative of the amino acid taurine. It was first synthesized in the 1970s and was originally used as a prophylactic against intraperitoneal...

  3. Drug

    Curcuma aromatica root oil

    go.drugbank.com/drugs/DB11301
    Approved

    Curcuma aromatica root oil is also suggested to have antibacterial activity. … The major constituents of Curcuma aromatica root oil are reported to be camphor, curzerenone, α-turmerone, ar-turmerone and 1,8-cineole [A27219].

  4. Drug

    Ipilimumab

    go.drugbank.com/drugs/DB06186
    ApprovedInvestigational

    Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol...

  5. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    By replacing deficient ALP, treatment with Asfotase Alfa aims to improve the elevated enzyme substrate levels and improve the body's ability to mineralize bone, thereby preventing serious skeletal and … Asfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP).

  6. Drug

    Pentamidine

    go.drugbank.com/drugs/DB00738
    ApprovedInvestigational

    Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other t...

  7. Drug

    Eravacycline

    go.drugbank.com/drugs/DB12329
    ApprovedInvestigational

    Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections [A38727]. … This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority

  8. Drug

    Tisotumab vedotin

    go.drugbank.com/drugs/DB16732
    ApprovedInvestigational

    Tisotumab vedotin targets TF-expressing cells to deliver MMAE to induce direct cytotoxicity and bystander killing of neighboring cells. … Tisotumab vedotin is the first TF-directed ADC [A238914] that works by binding to TFs expressed on solid tumours.

  9. Drug

    Cloperastine

    go.drugbank.com/drugs/DB09002
    Investigational

    Cloperastine is a cough suppressant that acts on the central nervous system.

    Mixtures: Facol Classic One
  10. Drug

    Zoliflodacin

    go.drugbank.com/drugs/DB12817
    ApprovedInvestigational

    Gonorrhea, caused by Neisseria gonorrhoeae, presents a significant public health challenge due to increasing antimicrobial resistance. … [A275268] Zoliflodacin is a first-in-class spiropyrimidinetrione antibiotic designed to address this need by inhibiting bacterial type II topoisomerases (DNA gyrase and topoisomerase IV), thereby blocking